drugset / Trial / NCT06642844
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Phase 3
Recruiting
244 enrolled
University Hospital, Tours
AP-HP, Hôpital Henri Mondor · collabAP-HP, Hôpital Saint-Louis · collabCHG de St-Malo · collabCHU DE BESANCON · collabCHU de Brest · collabCHU de Reims · collabCentral Hospital, Nancy, France · collabCentre Hospitalier Universitaire Dijon · collabCentre Hospitalier Universitaire, Amiens · collabGustave Roussy, Cancer Campus, Grand Paris · collabHCL Hôpital Edouard Hériot · collabHopital Paul Brousse · collabHôpital Privé Jean Mermoz · collabInstitut Paoli-Calmettes · collabNantes University Hospital · collabPitié-Salpêtrière Hospital · collabPoitiers University Hospital · collabPolyclinique de Blois · collabRennes University Hospital · collabUniversity Hospital, Caen · collabUniversity Hospital, Clermont-Ferrand · collabUniversity Hospital, Rouen · collabUniversity Hospital, Toulouse · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response relationship for efficacy was described for bevacizumab in mCRC patients treated with 1st-line bevacizumab-based chemotherapy.
Timeline
- Start
- 2025-03-04
- Primary completion
- 2028-03-04
- Completion
- 2029-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |